Mecolzine (Mesalazine)

Mesalazine acts locally in the intestinal lining by inhibiting cyclooxygenase and lipoxygenase enzymes, which lowers prostaglandin and leukotriene production. It also scavenges free radicals, resulting in reduced mucosal inflammation and relief of bowel symptoms.

The dosage of Mecolzine is individualized by the prescribing clinician based on disease severity, patient weight, and response to therapy. Physicians determine the appropriate strength, frequency, and duration, and patients should follow the prescribed regimen exactly.

Safety data for mesalazine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers will assess each case and advise accordingly.

To request Mecolzine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to mesalazine is sulfasalazine, another aminosalicylate that requires metabolic activation and may cause more systemic side effects such as hypersensitivity. Mesalazine delivers the active moiety directly to the colon, often resulting in a better tolerability profile for many patients.

Mecolzine should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout its shelf life.

Mecolzine is administered orally, usually with a full glass of water. It can be taken with or without food, but consistent intake with respect to meals helps maintain steady drug levels. Patients should swallow tablets whole and not crush or chew them unless directed by a healthcare professional.

Serious adverse events include severe allergic reactions (anaphylaxis), pancreatitis, significant blood‑cell abnormalities, liver enzyme elevations, interstitial nephritis, and worsening of colitis. Patients should seek immediate medical attention if they experience symptoms such as rash, fever, abdominal pain, jaundice, or unexplained bruising.

Mecolzine is contraindicated in individuals with known hypersensitivity to mesalazine or any component of the formulation. Patients with severe renal or hepatic impairment should avoid use unless closely monitored, and those with a history of severe allergic reactions to related drugs should not be prescribed this medication.